semaglutide fda approved for weight loss (wegovy) FDA approves obesity drug that

This takes a few minutes but provides definitive confirmation

Any treatment plan involving these agents should include: Regular blood tests (glucose, HbA1c, IGF-1, lipids, liver function, renal function) Documented informed consent regarding off-label or investigational use Dietitian input to monitor nutritional status, particularly during periods of rapid weight loss or reduced appetite Reconciliation of all concomitant medicines , including over-the-counter products and supplements, to minimise interaction risks Clear escalation pathways if side effects arise, including urgent review for severe abdominal pain, dehydration, or hypoglycaemia Ongoing review by a named responsible clinician Reporting of any suspected adverse effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) Your health and safety are best protected by working transparently within the NHS or a regulated private medical setting, with full disclosure of all medicines prescribed or otherwise that you are taking

Worth it for these numbers

Gentler on the body: A gradual approach can feel less extreme, especially for those who are metabolically sensitive

If you're switching to a more potent GLP-1 drug (e.g., semaglutide to tirzepatide), your insulin or sulfonylurea dose may need to decrease